全文获取类型
收费全文 | 95872篇 |
免费 | 6719篇 |
国内免费 | 4160篇 |
专业分类
耳鼻咽喉 | 385篇 |
儿科学 | 1715篇 |
妇产科学 | 973篇 |
基础医学 | 14689篇 |
口腔科学 | 1866篇 |
临床医学 | 9231篇 |
内科学 | 16419篇 |
皮肤病学 | 1148篇 |
神经病学 | 8220篇 |
特种医学 | 1810篇 |
外国民族医学 | 16篇 |
外科学 | 6464篇 |
综合类 | 16243篇 |
现状与发展 | 23篇 |
预防医学 | 5613篇 |
眼科学 | 1011篇 |
药学 | 11954篇 |
16篇 | |
中国医学 | 3104篇 |
肿瘤学 | 5851篇 |
出版年
2024年 | 191篇 |
2023年 | 1014篇 |
2022年 | 2497篇 |
2021年 | 3472篇 |
2020年 | 2803篇 |
2019年 | 2434篇 |
2018年 | 2416篇 |
2017年 | 2688篇 |
2016年 | 3045篇 |
2015年 | 3402篇 |
2014年 | 5834篇 |
2013年 | 6617篇 |
2012年 | 6094篇 |
2011年 | 6727篇 |
2010年 | 5447篇 |
2009年 | 5331篇 |
2008年 | 5466篇 |
2007年 | 5377篇 |
2006年 | 4723篇 |
2005年 | 4448篇 |
2004年 | 3679篇 |
2003年 | 3142篇 |
2002年 | 2405篇 |
2001年 | 2087篇 |
2000年 | 1797篇 |
1999年 | 1589篇 |
1998年 | 1447篇 |
1997年 | 1281篇 |
1996年 | 1114篇 |
1995年 | 929篇 |
1994年 | 845篇 |
1993年 | 710篇 |
1992年 | 610篇 |
1991年 | 572篇 |
1990年 | 488篇 |
1989年 | 386篇 |
1988年 | 373篇 |
1987年 | 350篇 |
1986年 | 304篇 |
1985年 | 445篇 |
1984年 | 398篇 |
1983年 | 262篇 |
1982年 | 306篇 |
1981年 | 241篇 |
1980年 | 224篇 |
1979年 | 150篇 |
1978年 | 137篇 |
1977年 | 106篇 |
1976年 | 99篇 |
1975年 | 72篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
31.
《Vaccine》2019,37(31):4382-4391
Cancer-associated fibroblasts (CAFs), major components of the tumor microenvironment (TME), promote tumor growth and metastasis and inhibit the anti-tumor immune response. We previously constructed a DNA vaccine expressing human FAPα, which is highly expressed by CAFs, to target these cells in the TME, and observed limited anti-tumor effects in the 4T1 breast cancer model. When the treatment time was delayed until tumor nodes formed, the anti-tumor effect of the vaccine completely disappeared. In this study, to improve the safety and efficacy, we constructed a new FAPα-targeted vaccine containing only the extracellular domain of human FAPα with a tissue plasminogen activator signal sequence for enhanced antigen secretion and immunogenicity. The number of CAFs was more effectively reduced by CD8+ T cells induced by the new vaccine. This resulted in decreases in CCL2 and CXCL12 expression, leading to a significant decrease in the ratio of myeloid-derived suppressor cells in the TME. Moreover, when mice were treated after the establishment of tumors, the vaccine could still delay tumor growth. To facilitate the future application of the vaccine in clinical trials, we further optimized the gene codons and reduced the homology between the vaccine and the original sequence, which may be convenient for evaluating the vaccine distribution in the human body. These results indicated that the new FAPα-targeted vaccine expressing an optimized secreted human FAPα induced enhanced anti-tumor activity by reducing the number of FAPα+ CAFs and enhancing the recruitment of effector T cells in the 4T1 tumor model mice. 相似文献
32.
《Vaccine》2019,37(24):3234-3240
Leucine aminopeptidase (FhLAP) and cathepsin L1 (FhCL1) of Fasciola hepatica play a critical role in parasite feeding, migration through host tissue, and immune evasion. These antigens have been tested for immune protection as single components with variable degrees of success. The chimeric-protein approach could improve protection levels against fasciolosis. Previously, we reported the design and construction of a chimeric protein composed of antigenic sequences of FhLAP and FhCL1 of F. hepatica. The goal of the present study was to express and evaluate the immune-protective capacity of this chimeric protein (rFhLAP-CL1) in sheep. Animals were randomly allocated into five groups with five animals in each group. Groups 1, 2 and 3 were immunized twice with 100 μg, 200 μg and 400 μg of rFhLAP-CL1 emulsified with Quil A adjuvant, whereas groups 4 and 5 were the adjuvant control and infection control groups, respectively. The animals were then challenged with 200 metacercariae two weeks after the rFhLAP-CL1 booster. The fluke burden was reduced by 25.5%, 30.7% (p < 0.05) and 46.5% (p < 0.01) in sheep immunized with 100 μg, 200 μg and 400 μg of chimeric protein, respectively, in comparison to the infection control group. There was a reduction of 22.7% (p < 0.05) and 24.4% (p < 0.01) in fecal egg count in groups 2 and 3, respectively, compared to the infection control group. Sheep immunized with chimeric protein produced F. hepatica excretion-secretion product-specific total IgG antibody, which were increased after challenge. Moreover, the levels of rFhLAP-CL1-specific IgG1 and IgG2 isotypes in immunized sheep increased rapidly two weeks after the first immunization and were significantly more elevated than those of the control groups, indicating a mixed Th1/Th2 response. This is a preliminary evaluation of the chimeric protein rFhLAP-CL1 as a possible immunogen against F. hepatica infection in sheep. 相似文献
33.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献34.
This study aimed to observe the therapeutic effects of magnesium lithospermate B on acute and chronic colitis induced by dextran sodiumsulfate (DSS) and the role of inflammasome complex (NOD-like receptor protein, NLRP; apoptosis-associated speck-like protein containing, ASC; caspase-1). Establishment of acute and chronic colitis models were by using 5% DSS oral administration in BALB/C male mice. Magnesium lithospermate B (240 mg/kg body weight) was given by subcutaneous injection. Samples were collected for biomarker assay, histological examination, immunohistochemical evaluation and western blot. There was obvious increase in TNF-α level and NLPR3, ASC, and caspase-1 expressions in acute and chronic colitis groups compared with the normal control. Significant decrease of the tumor necrosis factor-α level and the expressions of NLPR3, ASC, and caspase-1 were observed after treatment with magnesium lithospermate B. This study showed that magnesium lithospermate B could be used to treat acute and chronic colitis by inhibiting the activation of the NLRP3/ASC/Caspase-1 pathway. 相似文献
35.
Walid K. Abu Saleh Phillip Mason Odeaa Al Jabbari Hany Samir Brian A. Bruckner 《Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital》2015,42(6):569-571
The Impella 5.0, a percutaneously inserted left ventricular assist device, has been used to support patients who have severe heart failure or who are undergoing high-risk percutaneous coronary intervention. We report our surgical placement of the Impella 5.0, through a graft sewn to the aorta, to unload the left ventricle of a 59-year-old man who was undergoing venoarterial extracorporeal membrane oxygenation for postcardiotomy shock. The patient underwent successful placement of a long-term left ventricular assist device before his discharge from the hospital. The versatility of the Impella 5.0 is exemplified in this patient who was successfully bridged to long-term support. 相似文献
36.
目的 探讨γ干扰素诱导蛋白30(IFI 30)、程序性死亡因子配体1(PD-L1)在人脑胶质瘤中的表达及与病人预后的关系。方法 选择2015年5月~2019年5月手术切除的103例人脑胶质瘤组织和瘤旁组织,采用免疫组织化学染色检测IFI 30、PD-L1表达情况。随访24个月,记录无进展生存期和总生存期。结果 胶质瘤组织IFI 30、PD-L1高表达率[分别为70.87%(73/103)、68.93%(71/103)]明显高于瘤旁组织[分别为19.42%(20/103)、21.36%(22/103);P<0.001]。胶质瘤组织IFI 30表达水平与PD-L1表达水平呈明显正相关(r=0.583,P<0.05)。随访24个月,生存75例,死亡28例;多因素logistic回归分析显示,IFI 30高表达、PD-L1高表达是增加病人死亡风险的独立危险因素(P<0.05)。生存曲线分析显示,IFI 30高表达组2年累积生存率(64.52%)和2年累积无进展生存率(65.56%)均明显低于低表达组(分别为82.25%、89.45%;P<0.05)。PD-L1高表达组2年累积生存率(61.78%)和2年累积无进展生存率(60.14%)均明显低于低表达组(分别为88.52%、79.86%;P<0.05)。结论 人脑胶质瘤组织IFI 30、PD-L1呈高表达,与病人不良预后密切相关。 相似文献
37.
38.
目的:总结富亮氨酸胶质瘤失活1蛋白(LGI1)抗体阳性边缘性脑炎的临床和影像特点及诊疗预后。
方法:报道我院1例LGI1抗体阳性相关边缘性脑炎并文献复习。结果:患者女性,60岁,表现为渐进性加重
的记忆力减退、癫痫发作(全身强直阵挛发作,面-臂肌张力障碍发作)、低钠血症和轻度精神行为异常。颅 脑MRI-T2/Flair序列提示双侧颞叶(左侧为甚)内侧、海马异常高信号。脑脊液抗LGI1抗体阳性(++)。经激
素治疗症状有所改善。检索既往报道LGI1抗体阳性边缘性脑炎患者237例,多数呈急性、亚急性起病,最
常见是记忆障碍、癫痫(含面-臂肌张力障碍发作)和低钠血症,头颅MRI(特别是MRI-T2/Flair序列)显示单
侧或者双侧海马区、颞叶异常多见,早期免疫治疗预后良好。结论:LGI1抗体阳性相关边缘性脑炎有其特
有的临床特点,免疫治疗可明显改善患者预后。 相似文献
39.
随着对肿瘤热疗和肿瘤免疫微环境(TIME)的深入研究,近年来热疗对TIME的作用越来越受到学者们的重视。本文就目前国内外研究进展,对热疗与TIME中几类主要免疫细胞和免疫相关细胞因子的影响及作用机制作一综述。全面而透彻的了解热疗对TIME的调控作用,有助于为肿瘤治疗提供新的思路和方法。 相似文献
40.
目的:观察灯盏乙素(Scu)对β淀粉样蛋白(Aβ)诱导的细胞模型中1,4,5-三磷酸肌醇受体(IP3R)-Ca2+途径的影响,探讨其在阿尔茨海默病(AD)病程中可能发挥的积极作用。方法:选用神经母细胞瘤细胞分为对照组、Scu处理组、Aβ处理组、Aβ+Scu (高、中、低)处理组及Aβ+IP3R拮抗剂组,用CCK-8法筛选药物浓度并检测各组细胞生存率;用酶联免疫吸附法检测各组细胞中1,4,5-三磷酸肌醇(IP3)的含量;用蛋白印迹和实时荧光定量聚合酶链反应方法检测各组细胞IP3R和凋亡相关因子Caspase-3、Bcl-2、Bax的蛋白及mRNA的表达水平;用激光共聚焦显微镜观察各组细胞内Ca2+浓度的变化;用AnnexinV/PI双染法测定各组细胞的凋亡率。结果:与对照组和Scu处理组相比,Aβ处理组细胞存活率下降,IP3含量升高,IP3R、Bax和Caspase-3的蛋白及mRNA表达上调,Bcl-2蛋白及mRNA的表达下调,细胞胞浆内Ca2+浓度及细胞凋亡率升高;Aβ+Scu处理组细胞中各检测指标的变化与Aβ处理组的结果正好相反,IP3R通道下游指标的变化与Aβ+IP3R拮抗剂组基本一致。结论:Scu能够下调通路蛋白IP3、IP3R的表达,抑制Aβ介导的Ca2+内流所致的细胞凋亡,可能通过对IP3R-Ca2+途径的调控来影响AD病程。 相似文献